Henry Schein (HSIC) announced that it has signed an agreement to acquire Acentus, a national medical supplier specializing in the delivery of Continuous Glucose Monitors. The Acentus transaction follows Henry Schein’s acquisition of Prism Medical Products, LLC in 2021 and Shield Healthcare and Mini Pharmacy in 2023, reinforcing the company’s strategic commitment to the homecare medical supplies market. Henry Schein’s homecare medical products platform will now have an annual revenue base of approximately $350M. With annual revenue of approximately $35M, Acentus is headquartered in Tampa, Florida. Henry Schein expects the transaction to be neutral to 2024 non-GAAP earnings per share and accretive thereafter. Closing is subject to standard closing conditions and is expected to be completed in the first quarter of 2025. Financial terms were not disclosed.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HSIC:
- Ananym urges Henry Schein to cut spending, sell unit, Reuters reports
- Henry Schein management to meet with Piper Sandler
- Early notable gainers among liquid option names on November 18th
- Henry Schein participates in a conference call with JPMorgan
- Henry Schein Updates 2024 Financial Guidance Amid Solid Q3
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
